Regeneron Pharmaceuticals Inc

1. 01

   Set a 52-week high on 4 Nov 2026

   Closed at $930.67 on 4 Nov 2026: 6.2% below the 52-week high of $991.73 (4 Nov 2026) and 57.3% above the low of $591.52 (2 Jun 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

2. 02

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +26.0% (SPY −1.6%, XLV +13.5%). 3 months: +21.1% (SPY −0.4%, XLV +15.5%). 1 year: +48.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: REGN, SPY and XLV · as of 4 Nov 2026

3. 03

   P/E 52.2% below its peers' median

   Trailing P/E of 21.5 against a median of 45.0 across 4 peers named in its company record (range 35.3 to 120.3).

   Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 5 Nov 2026

4. 04

   Above its 50- and 200-day averages

   The 4 Nov 2026 close of $930.67 was 16.2% above its 50-day average ($800.69) and 25.6% above its 200-day average ($740.82). It has closed above the 200-day for 22 sessions, since 6 Oct 2026. The 50-day average crossed above the 200-day on 3 Sep 2026, 43 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

5. 05

   Volume 1.7× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 1.4M shares was 1.7× the average of the 30 sessions before it (805.5K), as the price fell 4.4%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close